Table 2.

Role of statins in multiple sclerosis (MS)

Study type	Findings	References
A placebo-controlled clinical Trial	Different statins for 24 months reduced disease severity in patients with MS	Wang et al. [137]
A review	Statins may have neuroprotective and neuro-repairing effects in clinical MS and experimental autoimmune encephalomyelitis	Xu et al. [146]
Double-blind randomized controlled trial	Atorvastatin 40 mg/kg for 18 months reduced severity and relapse in MS patients	Ghasami et al. [147]
Multicenter double-blind placebo-controlled phase II Trials	Simvastatin 80 mg/kg for 24 months reduced severity and relapse in MS patients	Chataway et al. [148]
A systematic review and meta-analysis	No benefit from statin treatment as an add-on to interferon beta (IFN-β) in MS patients	Stefanou et al. [149]